Xsensio, a Lausanne-based DeepTech firm growing close to real-time steady biochemical monitoring, introduced the profitable closing of a €6 million ($7 million) oversubscribed Sequence A financing spherical.
The spherical was led by VC agency WI Harper, with participation from Privilège Ventures, the European Innovation Council, and personal buyers throughout america, Europe, and Asia.
“This Sequence A marks a pivotal step in translating steady biochemical monitoring into actual medical environments,” says Esmeralda Megally, CEO of Xsensio. “For the primary time, clinicians can entry key steady biochemical information in actual time, data that has traditionally been unavailable on the level of care. This functionality has the potential to basically enhance how sufferers are monitored and handled.”
Xsensio operates inside a European wearable and steady biosensing section that has seen sustained funding momentum all through 2025 and early 2026.
In July 2025, London-based Sava Technologies secured €16.6 million in a Sequence A spherical to advance its wearable molecular well being monitoring microsensor expertise and progress in direction of regulatory approval and commercialisation. Earlier in February 2025, London-based Level Zero Health raised €6.6 million in pre-Seed funding to develop what it describes because the world’s first steady hormone monitoring wearable. In Switzerland, Liom closed a €13.9 million spherical in December 2025 to additional its non-invasive steady glucose monitoring expertise. In the meantime, Zurich-based Ahead Health raised €5.1 million in January 2026 to increase its preventive healthcare testing and analytics platform.
Collectively, these disclosed rounds quantity to over €42 million invested into European startups growing steady or wearable well being monitoring options throughout 2025 and early 2026, offering sector context for Xsensio’s €6 million Sequence A and indicating continued capital allocation in direction of real-time, data-driven healthcare monitoring applied sciences.
“Our collaboration with Texas Devices considerably strengthens our path to superior, scalable semiconductor expertise,” provides Adrian Ionescu, CTO of Xsensio. “By combining our biosensing innovation with world-class semiconductor experience, we’re constructing a platform designed not just for medical influence, but additionally for dependable, cost-effective deployment.”
Based in 2014, Xsensio is growing the Lab-on-Pores and skin wearable biosensing platform to ship steady, real-time biochemical data for personalised and preventive healthcare.
Developed on the Nanolab of the Swiss Federal Institute of Know-how, this primary product focuses on early detection of organ dysfunction, addressing high-impact challenges in essential care, oncology, and post-surgical restoration. The sensing chip analyses biomarkers within the interstitial fluid (ISF) – the physique’s pure window into irritation, metabolism, and organ perform.
The chip integrates a number of sensors focusing on a spread of biomarkers – from metabolites and ions to proteins and hormones. Its modular and customisable structure allows them to adapt the identical platform throughout various medical use circumstances. All information is made securely accessible in actual time to sufferers, caregivers, or healthcare suppliers, enabling earlier interventions and extra personalised care.
Xsensio is growing a scalable and proprietary platform of wearable services, all constructed on their core Lab-on-Pores and skin system. Every resolution combines:
-
Their customised multi-sensor chip
-
A proprietary pores and skin interface
-
Wi-fi communication for on-demand or steady information streaming
“We imagine Xsensio is defining a brand new class in wearable biosensing. Given the corporate’s sturdy progress and market potential, we’re excited to be main this funding spherical,” shares Wilson Wu, Companion at WI Harper.
Together with the funding, Xsensio introduced a long-term collaboration with Texas Devices, a world chief in semiconductor expertise. This collaboration brings distinctive experience in CMOS integration, miniaturisation, and large-scale manufacturability of biosensing programs, additional strengthening Xsensio’s industrial scalability.
